Abstract
Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.
| Original language | English |
|---|---|
| Pages (from-to) | 38-40 |
| Number of pages | 3 |
| Journal | Clinical and Diagnostic Laboratory Immunology |
| Volume | 5 |
| Issue number | 1 |
| State | Published - Jan 1 1998 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Clinical Biochemistry
- Immunology
- Immunology and Allergy
- Microbiology (medical)
Cite this
Distribution of CCR5δ32 in human immunodeficiency virus-infected children and its relationship to disease course. / Bakshi, Saroj S.; Zhang, Linqi; Ho, David; Than, Soe; Pahwa, Savita G.
In: Clinical and Diagnostic Laboratory Immunology, Vol. 5, No. 1, 01.01.1998, p. 38-40.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Distribution of CCR5δ32 in human immunodeficiency virus-infected children and its relationship to disease course
AU - Bakshi, Saroj S.
AU - Zhang, Linqi
AU - Ho, David
AU - Than, Soe
AU - Pahwa, Savita G
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.
AB - Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.
UR - http://www.scopus.com/inward/record.url?scp=0031594461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031594461&partnerID=8YFLogxK
M3 - Article
C2 - 9455877
AN - SCOPUS:0031594461
VL - 5
SP - 38
EP - 40
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
SN - 1556-6811
IS - 1
ER -